See more : Secoo Holding Limited (SECO) Income Statement Analysis – Financial Results
Complete financial analysis of Ra Medical Systems, Inc. (RMED) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ra Medical Systems, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Ningbo Zhenyu Technology Co., Ltd. (300953.SZ) Income Statement Analysis – Financial Results
- Zhejiang HangKe Technology Incorporated Company (688006.SS) Income Statement Analysis – Financial Results
- Cerinnov Group SA (ALPCV.PA) Income Statement Analysis – Financial Results
- Qingdao Baheal Medical INC. (301015.SZ) Income Statement Analysis – Financial Results
- Eltel AB (publ) (0R53.L) Income Statement Analysis – Financial Results
Ra Medical Systems, Inc. (RMED)
About Ra Medical Systems, Inc.
Ra Medical Systems, Inc., a medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular immune-mediated inflammatory diseases. It offers destruction of arteriosclerotic blockages by laser radiation ablation, a minimally invasive excimer laser and single-use catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. The company sells its products primarily through distributors in the United States. Ra Medical Systems, Inc. was incorporated in 2002 and is headquartered in Carlsbad, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 14.00K | 22.00K | 4.41M | 7.20M | 6.26M | 5.87M | 5.98M |
| Cost of Revenue | 161.00K | 1.56M | 5.48M | 8.85M | 4.21M | 4.17M | 3.14M |
| Gross Profit | -147.00K | -1.54M | -1.08M | -1.65M | 2.05M | 1.71M | 2.84M |
| Gross Profit Ratio | -1,050.00% | -6,990.91% | -24.45% | -22.93% | 32.78% | 29.05% | 47.49% |
| Research & Development | 6.39M | 12.25M | 9.01M | 4.53M | 2.78M | 4.52M | 1.72M |
| General & Administrative | 2.23M | 0.00 | 0.00 | 0.00 | 30.44M | 0.00 | 0.00 |
| Selling & Marketing | 1.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.25M | 15.48M | 25.97M | 51.55M | 30.44M | 14.95M | 5.32M |
| Other Expenses | 99.00K | 2.01M | 21.00K | 788.00K | 338.00K | 0.00 | 0.00 |
| Operating Expenses | 22.64M | 27.73M | 34.98M | 56.08M | 33.21M | 19.47M | 7.04M |
| Cost & Expenses | 22.80M | 29.29M | 40.46M | 64.93M | 37.42M | 23.63M | 10.17M |
| Interest Income | 0.00 | 0.00 | 129.00K | 1.04M | 352.00K | 0.00 | 0.00 |
| Interest Expense | 3.08M | 0.00 | 108.00K | 250.00K | 14.00K | 4.00K | 3.00K |
| Depreciation & Amortization | 8.77M | 1.57M | 2.37M | 1.75M | 624.00K | 218.00K | 95.00K |
| EBITDA | -18.20M | -29.27M | -36.06M | -57.73M | -31.16M | -17.54M | -4.10M |
| EBITDA Ratio | -129,971.43% | -133,027.27% | -818.59% | -801.92% | -498.00% | -298.84% | -68.66% |
| Operating Income | -26.96M | -29.27M | -36.06M | -57.73M | -31.16M | -17.76M | -4.20M |
| Operating Income Ratio | -192,578.57% | -133,027.27% | -818.59% | -801.92% | -498.00% | -302.56% | -70.25% |
| Total Other Income/Expenses | 3.00K | 2.01M | 21.00K | 788.00K | 338.00K | -4.00K | -3.00K |
| Income Before Tax | -26.86M | -27.26M | -36.04M | -56.94M | -30.82M | -17.76M | -4.20M |
| Income Before Tax Ratio | -191,871.43% | -123,895.45% | -818.12% | -790.97% | -492.60% | -302.62% | -70.30% |
| Income Tax Expense | 3.00K | 4.00K | 7.00K | 15.00K | 10.00K | 1.00K | 1.00K |
| Net Income | -26.87M | -27.26M | -36.05M | -56.96M | -30.83M | -17.77M | -4.20M |
| Net Income Ratio | -191,892.86% | -123,913.64% | -818.27% | -791.18% | -492.76% | -302.64% | -70.31% |
| EPS | -25.98 | -269.91 | -1.06K | -5.42K | -4.18K | -1.83K | -433.96 |
| EPS Diluted | -25.98 | -269.91 | -1.06K | -5.42K | -4.18K | -1.83K | -433.96 |
| Weighted Avg Shares Out | 1.03M | 101.00K | 33.98K | 10.52K | 7.38K | 9.68K | 9.68K |
| Weighted Avg Shares Out (Dil) | 1.03M | 101.00K | 33.98K | 10.52K | 7.38K | 9.68K | 9.68K |
Ra Medical to Hold 2018 Fourth Quarter and Full Year Conference Call on March 14, 2019
Ra Medical Systems to Report Third Quarter 2018 Results on November 13, 2018
Source: https://incomestatements.info
Category: Stock Reports